Boillhealthcare (01246.HK) announced on August 9th that the Stock Exchange has informed the company on July 26th, 2024 that it must comply with the following resumption guidance before seeking resumption of trading: (i) provide appropriate evidence to the Stock Exchange to prove and convince it of the correct identity, position and function of the company's board members; and (ii) disclose all material information to the market for shareholders and investors to assess the status of the company.

The company's right to use the Stock Exchange's electronic submission system has also been suspended until the composition of its board of directors and the identity of the authorized person for the electronic submission system account have been clarified.